Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA, Inc. with USD 38 Mn addressable opportunity

Senores Pharmaceuticals Limited has signed an agreement with Teva Pharmaceuticals USA, Inc. to acquire two USFDA approved Abbreviated New Drug Applications (ANDAs) through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA. The acquired ANDAs present an addressable opportunity of approximately USD 38 Mn (MAT December 2024) as per IQVIA and USD 120 Mn (MAT June 2025) as per Symphony. The acquisition will be funded using the Initial Public Offer (IPO) proceeds raised by SPL. Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products for the US, Canada, and other regulated and emerging markets. The company has a diverse portfolio of 70 ANDA and 27 CMO/CDMO commercial products, as well as 308 product registrations and 719 product applications in emerging markets.